Abstract
Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. To prospectively map the landscape of resistance to this investigational regimen, we utilized a series of gain- and loss-of-function forward genetic screens to identify modulators of resistance to clinical inhibitors of MEK1/2 and CDK4/6 alone and in combination. First, we identified NRAS-mutant melanoma cell lines that were dependent on NRAS for proliferation and sensitive to MEK1/2 and CDK4/6 combination treatment. We then used a genome-scale ORF overexpression screen and a CRISPR knockout screen to identify modulators of resistance to each inhibitor alone or in combination. These orthogonal screening approaches revealed concordant means of achieving resistance to this therapeutic modality, including tyrosine kinases, RAF, RAS, AKT, and PI3K signaling. Activated KRAS was sufficient to cause resistance to combined MEK/CDK inhibition and to replace genetic depletion of oncogenic NRAS. In summary, our comprehensive functional genetic screening approach revealed modulation of resistance to the inhibition of MEK1/2, CDK4/6, or their combination in NRAS-mutant melanoma. SIGNIFICANCE: These findings reveal that NRAS-...Continue Reading
References
Nov 8, 2005·Nature·David B SolitNeal Rosen
Feb 5, 2008·Cancer Research·William M LinLevi A Garraway
Nov 26, 2010·Nature·Cory M JohannessenLevi A Garraway
Feb 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfried E KonecnyDennis J Slamon
Jun 28, 2011·Nature Methods·Xiaoping YangDavid E Root
Sep 18, 2012·Nature Medicine·Lawrence N KwongLynda Chin
Feb 19, 2013·The Lancet Oncology·Paolo A AsciertoReinhard Dummer
Aug 13, 2013·Nature·Georgia HatzivassiliouMarcia Belvin
Nov 5, 2013·Nature·Cory M JohannessenLevi A Garraway
Jan 7, 2014·Molecular Cell·Timothy D MartinChanning J Der
Jun 21, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa ZimmerJean-Charles Soria
Jun 24, 2014·Cell·Diane D ShaoWilliam C Hahn
Jul 20, 2014·The Lancet Oncology·Antoni RibasGrant A McArthur
Dec 17, 2014·Proceedings of the National Academy of Sciences of the United States of America·Tanaz SharifniaMatthew Meyerson
Mar 12, 2015·Cancer Cell·Frederick H WilsonLevi A Garraway
Jan 5, 2016·Cancer Cell·Tikvah K HayesChanning J Der
Jan 19, 2016·Nature Biotechnology·John G DoenchDavid E Root
Sep 9, 2016·Cancer Discovery·Xiuning LeLevi A Garraway
Feb 9, 2017·Cell Reports·Belinda WangWilliam Chun Hahn
Mar 13, 2017·The Lancet Oncology·Reinhard DummerKeith Flaherty
Jul 29, 2017·Cell·Aviad TsherniakWilliam C Hahn
Jul 29, 2017·Cell·E Robert McDonaldWilliam R Sellers
Nov 1, 2017·ELife·Elsa Beyer KrallWilliam C Hahn
Dec 14, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R CondorelliA Bardia
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 3, 2018·Cancer Discovery·Jessica L F TehAndrew E Aplin
Mar 3, 2018·Cancer Discovery·Gabriele RomanoLawrence N Kwong
May 26, 2018·PloS One·Mudra HegdeJohn G Doench
Citations
Aug 14, 2019·Pigment Cell & Melanoma Research·Elisa BertoliAlessandro Marco Minisini
Jul 31, 2019·Journal of Translational Medicine·Longwen XuYan Kong
Apr 15, 2020·Cancer Cell·Mónica Álvarez-Fernández, Marcos Malumbres
Apr 1, 2021·Cell Reports·Eunice ChoBenjamin E Turk
May 1, 2021·International Journal of Molecular Sciences·Diana Valentina TudorGabriela Adriana Filip
May 1, 2021·Cancers·Kathryn M AppletonRichard R Neubig
Jun 3, 2021·Cells·Mattia GaruttiFabio Puglisi
Jun 8, 2021·Cancer Treatment Reviews·Tijana RandicStephanie Kreis
Jun 10, 2021·Expert Reviews in Molecular Medicine·Marika A V Reinius, Elizabeth Smyth
Jun 15, 2021·Frontiers in Oncology·Cristian ScatenaSara Tomei
Dec 7, 2021·Cancer Science·Shinya KitamuraHideyuki Ujiie